Rheumatoid factor (RF)

Pick Ordered or Not ordered to see the note.

Indicated when

• —Clinically suspicious arthralgia (persistent joint symptoms in a pattern concerning for inflammatory arthritis) or arthritis found on physical exam, i.e. one or more swollen joints [1]
• —Part of the work-up when rheumatoid arthritis is a real clinical consideration, alongside history, exam and acute-phase reactants; RF and ACPA together form the serologic domain of the 2010 ACR/EULAR RA classification criteria [3]

Not indicated when

• —Screening patients who have joint pain (arthralgia) but do not meet criteria for clinically suspicious arthralgia and have no arthritis on exam [1]
• —As a general 'autoimmune' or fatigue screen without joint findings

Why not

RF is only moderately specific for rheumatoid arthritis: a large meta-analysis found pooled sensitivity of 69% and specificity of 85% for IgM RF, compared with 67% sensitivity and 95% specificity for anti-CCP/ACPA [2]. RF can also be positive in other connective tissue diseases, chronic infections, and some healthy older adults, so ordering it without joint findings risks a false-positive result that prompts unnecessary rheumatology referral and anxiety without meaningfully changing management [1].

Better first step

Examine the joints first. Reserve RF (and ACPA, where accessible) for patients who meet clinically suspicious arthralgia criteria or have objective arthritis on exam, and interpret a positive result alongside the clinical picture and acute-phase reactants rather than in isolation.

Typical ND rationale

An ND may order RF in a patient with joint pain or generalized aches, reasoning that early detection of rheumatoid arthritis matters and that a simple blood test can help identify it before joint damage occurs.

Ontario coverage & CONO orderability

OHIP status

insured

RF bills through L500 'Screen for miscellaneous agglutination reactions', which names rheumatoid factor as an example alongside anti-thyroid and streptolysin screening, fee $3.10, with no restricting Essential Specifications paragraph identified, so it is insured when a physician orders it after clinically assessing the patient [4, 5]. This is an older agglutination-method screen; whether a modern automated RF immunoassay is billed under the same code was not confirmed this session. Anti-CCP/ACPA is funded only through the Community Access Pilot's Table 2, restricted to clinicians practising pediatrics, internal medicine (including rheumatology), or dermatology; other ordering clinicians, including family physicians and NDs, cannot access this funded pathway [6]. ND-ordered RF testing is patient-paid regardless [7].

CONO orderable

Yes — CONO list #110

CONO list item 110 'Rheumatoid factor', blood specimen. Anti-CCP/ACPA does not appear on the CONO list; it is not independently ND-orderable in Ontario, and even physician ordering under the funded pathway is restricted to specialists practising pediatrics, internal medicine (including rheumatology), or dermatology [6].

Linked conditions

• ra ↗
• tired ↗

Counselling script

“If your joints show signs of active inflammation, like swelling that's lasted a while, RF is a reasonable test, and catching rheumatoid arthritis early does make a real difference. Without swelling or a joint pattern typical of this disease, I wouldn't order it, because RF also comes back positive in a fair number of people who don't have rheumatoid arthritis, including some healthy older adults. If joint swelling develops, let's revisit this.”

Revisit if

• —Joint swelling or a pattern typical of inflammatory arthritis develops
• —RF positive with clinical suspicion: consider rheumatology referral for further evaluation, including ACPA

References

1. [1]Canadian Rheumatology Association / Choosing Wisely Canada (2024). Rheumatology: Eleven Tests and Treatments to Question. linkCRA/Choosing Wisely Canada: don't order RF and ACPA unless patients have clinically suspicious arthralgia or arthritis on exam
2. [2]Nishimura et al. (Harvard School of Public Health / Kobe University) (2007). Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. linkolder guidelinePooled sensitivity/specificity: IgM RF 69%/85%, anti-CCP 67%/95%; anti-CCP more specific for diagnosing rheumatoid arthritis
3. [3]American College of Rheumatology / European League Against Rheumatism (2010). 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. linkRF/ACPA form the serologic-abnormality domain of the 2010 ACR/EULAR RA classification criteria
4. [4]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026) - L500 Screen for miscellaneous agglutination reactions (anti-thyroid). linkL500 lists rheumatoid factor by name, insured, fee $3.10, no restriction identified
5. [5]Government of Ontario (e-Laws) (2026). Health Insurance Act, R.R.O. 1990, Reg. 552: General, s. 22 (insured laboratory services). linkInsured lab testing requires ordering by an authorized provider who has clinically assessed the patient
6. [6]Ontario Ministry of Health (2026). INFOBulletin 260503: 2026-2027 Community Access Pilot for Laboratory Services. linkAnti-CCP/ACPA is funded only through Community Access Pilot Table 2, ordering restricted to pediatrics, internal medicine (including rheumatology), and dermatology specialists
7. [7]Ontario Ministry of Health (2026). Ontario Health Insurance Plan: Schedule of Benefits for Laboratory Services (effective April 1, 2026). linkTests ordered by anyone other than an authorized provider, including NDs, are not insured services